← Back to Search
PD-L1 Expression Is Associated With Tumor-infiltrating T Cells And Favorable Prognosis In High-grade Serous Ovarian Cancer.
J. R. Webb, K. Milne, David R. Kroeger, B. Nelson
Published 2016 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
OBJECTIVE As a negative regulator of T cells, Programmed Death Ligand 1 (PD-L1) is both an indicator and inhibitor of anti-tumor immune responses, which has led to confusion about its prognostic significance. We investigated the primary source of PD-L1 expression in epithelial ovarian cancer and its relationship to tumor-infiltrating lymphocytes (TIL) and associated gene products. METHODS Tissue microarrays containing high-grade serous carcinomas (HGSC) and endometrioid, clear cell and mucinous ovarian cancers from optimally debulked patients were assessed by immunohistochemistry for expression of PD-L1 and other markers (CD68, CD3, CD8, PD-1, CD103, FoxP3 and CD25). The Cancer Genome Atlas was interrogated for associations between PD-L1 expression and immune-related transcriptional and genomic features of HGSC. RESULTS PD-L1 was primarily expressed by tumor-associated CD68(+) macrophages rather than tumor cells. PD-L1(+) cells frequently co-localized with CD8, CD4 and PD-1(+) TIL, CD25(+)FoxP3(+) Tregs, and other TIL subsets. PD-L1(+) cells were prognostically favorable in HGSC. Moreover, the presence of both PD-L1(+) cells and CD8 TIL was associated with better prognosis than CD8 TIL alone. PD-L1 gene expression was independent of BRCA status. At the transcriptional level, PD-L1 was associated with both cytolytic (granzyme B, T-bet and IFN-γ) and suppressive (PD-1, CTLA-4, LAG3 and IDO-1) gene products. CONCLUSIONS PD-L1 is primarily expressed by macrophages in ovarian cancer and is strongly associated with both cytolytic and regulatory TIL subsets, resulting in a net positive association with survival. Tumors containing PD-L1(+) macrophages appear caught in an immunological stalemate that may require multi-pronged immunotherapy to alleviate.
This paper references
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
J. R. Webb (2013)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.
M. Disis (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
J. Hamanishi (2015)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
B. Clarke (2009)
CD25 Identifies a Subset of CD4+FoxP3− TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer
R. deLeeuw (2014)
J. Sunshine (2015)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
K. Milne (2009)
New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.
B. Nelson (2015)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
Classifying Cancers Based on T-cell Infiltration and PD-L1.
M. Teng (2015)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
PD‐1 signaling in primary T cells
J. Riley (2009)
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
J. R. Webb (2015)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
T. Okazaki (2013)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
J. Taube (2012)
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
L. Zitvogel (2013)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
J. Taube (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
W. Cooper (2015)
Integrated Genomic Analyses of Ovarian Carcinoma
D. Bell (2011)
Overall survival and PD‐L1 expression in metastasized malignant melanoma
J. Gadiot (2011)
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
S. Kitazono (2015)
Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
Z. Gatalica (2015)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown (2014)
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Sofia Lyford-Pike (2013)
Overcoming T cell exhaustion in infection and cancer.
Kristen E. Pauken (2015)
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
A. Gros (2014)
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
A. Varga (2015)
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
K. Mahoney (2015)
The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
A. Kinter (2008)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
S. Darb-Esfahani (2016)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
M. Green (2010)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly (2014)
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
S. Wölfle (2011)
Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
D. Andorsky (2011)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
M. Köbel (2008)
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
M. Noman (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
This paper is referenced by
Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation
S. K. Parvathareddy (2021)
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
L. Wang (2019)
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
Karolina Okła (2020)
The antitumor effects of entinostat in ovarian cancer require adaptive immunity
H. Smith (2018)
Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction
Manja Idorn (2018)
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
P. Buderath (2019)
Targeting Programmed Cell Death ‐1 (PD‐1) and Ligand (PD‐L1): A new era in cancer active immunotherapy
A. Constantinidou (2019)
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes (2018)
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
M. Westergaard (2020)
Emerging biomarkers in ovarian granulosa cell tumors
A. Mills (2019)
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
H. Zhu (2016)
Factors in Oncogenesis: Viral Infections in Ovarian Cancer
S. Pathak (2020)
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
Liju Zong (2019)
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
J. Szender (2017)
An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (PD‐L1/2) on infiltrating macrophages in lymphoma
Hasita Horlad (2016)
Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
M. L. D. S. Lopes (2019)
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Laura Martin de la Fuente (2020)
Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
M. Pinto (2018)
Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy
M. Li (2017)
Targeting the Microenvironment in High Grade Serous Ovarian Cancer
Nkechiyere G. Nwani (2018)
Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.
Aras Toker (2019)
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
Graziela Zibetti Dal Molin (2018)
Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium
N. Johnson (2017)
Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study
J. F. Tierney (2019)
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
B. C. Willis (2017)
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
S. Nishio (2020)
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer
H. Liao (2018)
Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report.
Moss Bruton Joe (2017)
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma
C. Deng (2017)
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
G. Mittica (2016)
The role of immune checkpoint inhibition in the treatment of ovarian cancer
S. Gaillard (2016)
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma
P. Buderath (2019)See more